These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16810714)

  • 21. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
    Ramanathan S; Cheng A; Mittan A; Ebrahimi R; Kearney BP
    J Clin Pharmacol; 2006 May; 46(5):559-66. PubMed ID: 16638739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.
    Panhard X; Samson A
    Biostatistics; 2009 Jan; 10(1):121-35. PubMed ID: 18583352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
    J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir: what have over 1 million years of patient experience taught us?
    Pozniak A
    Int J Clin Pract; 2008 Aug; 62(8):1285-93. PubMed ID: 18705824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 30. Genetic basis of variation in tenofovir drug susceptibility in HIV-1.
    Murray RJ; Lewis FI; Miller MD; Brown AJ
    AIDS; 2008 Jun; 22(10):1113-23. PubMed ID: 18525256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
    Fux CA; Simcock M; Wolbers M; Bucher HC; Hirschel B; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Elzi L; Furrer H;
    Antivir Ther; 2007; 12(8):1165-73. PubMed ID: 18240857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.
    Retout S; Comets E; Samson A; Mentré F
    Stat Med; 2007 Dec; 26(28):5162-79. PubMed ID: 17486667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
    Subbarao S; Otten RA; Ramos A; Kim C; Jackson E; Monsour M; Adams DR; Bashirian S; Johnson J; Soriano V; Rendon A; Hudgens MG; Butera S; Janssen R; Paxton L; Greenberg AE; Folks TM
    J Infect Dis; 2006 Oct; 194(7):904-11. PubMed ID: 16960777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of tenofovir on renal glomerular and tubular function.
    Fux CA; Christen A; Zgraggen S; Mohaupt MG; Furrer H
    AIDS; 2007 Jul; 21(11):1483-5. PubMed ID: 17589197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug interactions. Brecanavir--a new protease inhibitor.
    TreatmentUpdate; 2006; 18(3):6-7. PubMed ID: 17209240
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-HIV agents. No interaction between tenofovir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17216838
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques.
    Van Rompay KK; Hamilton M; Kearney B; Bischofberger N
    Antimicrob Agents Chemother; 2005 May; 49(5):2093-4. PubMed ID: 15855535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
    Nguyen TT; Bazzoli C; Mentré F
    Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.